C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 417/12 (2006.01) A61K 9/06 (2006.01) A61K 9/08 (2006.01) A61K 31/4439 (2006.01) A61P 27/02 (2006.01) A61P 27/04 (2006.01) A61P 27/14 (2006.01)
Patent
CA 2566098
A new medicinal application of 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]- 2,4-thia~zolidinedione or 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]~phenyl]methyl]- 2,4-thiazolidinedione. 5-[p-[2-(methyl-2~pyridylamino)ethoxy]benzyl]-2,4- thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- 2,4~thiazolidine-dione, or a salt of either produces an excellent mitigating effect on corneal-disorder models and is hence useful as a therapeutic agent for keratoconjunctiva disorders such as dry eye, corneal ulcer, corneitis, and conjunctivitis.
Une nouvelle application médicale de 5-[p-[2-(méthyl-2-pyridylamino)éthoxy]benzyle]-2,4-thiazolidinédione ou de 5-[[4-[2-(5-éthyl-2-pyridinyl)éthoxy]phényle]méthyle]-2,4-thiazolidinédione. La 5-[p-[2-(méthyl-2-pyridylamino)éthoxy]benzyle]-2,4-thiazolidinédione, la 5-[[4-[2-(5-éthyl-2-pyridinyl)éthoxy]phényle]méthyle]-2,4-thiazolidinédione ou un sel de l'une ou l'autre produit un excellent effet d'atténuation sur les modèles des affections de la cornée, et est donc utile en tant qu'agent thérapeutique pour les affections de kératoconjonctivite telles que la kératoconjonctivite sèche, l'ulcération de la cornée, la kératite et la conjonctivite.
Hirai Shin-Ichiro
Nakamura Masatsugu
Fetherstonhaugh & Co.
Santen Pharmaceutical Co. Ltd.
LandOfFree
Therapeutic agent for keratoconjunctival disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for keratoconjunctival disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for keratoconjunctival disorder will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1938414